for appointments 716.250.2000

Current Research

If you would like to inquire about or participate in research projects at DENT, please contact us at 716-250-2038 for additional information. Below is a listing of our current studies.

ALZHEIMER’S RESEARCH

 AN2401-G000-201

 Need little reminders more often?

         

If you’re at least 50 years of age and have noticeable changes in your memory, judgment or ability to perform your daily activities, you may qualify for the BAN study. This study will evaluate an investigational drug for memory and thinking.

If you qualify, you’ll receive:

·         Study-related diagnostic procedures that may provide insight in to your thinking and memory issues,

·         Continuous medical monitoring of your condition,

·         Possible reimbursement for travel

 

For more information, contact:

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

 

 

HCA-MC-LZAX

Looking for something?

 

So are we – people with memory or thought processing problems.

·         Have you noticed a gradual decline in your memory?

·         Could you have mild Alzheimer’s disease?

·         Are you between 55 and 90 years of age?

If this sounds like you, consider EXPEDITION 3 – a clinical research study looking at investigational drug for mild Alzheimer’s disease. Study-related treatments and procedures will be free of charge.

 

For more information, contact:

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

Caroline Kumm: 716-250-2000 x4171

 

Additional Alzheimer’s research studies coming soon. Contact us for details!

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

Caroline Kumm: 716-250-2000 x4171

 

MULTIPLE SCLEROSIS RESEARCH

          Assess – Fingolimod

          Do you suffer from relapsing-remitting multiple sclerosis?

If you have relapsing-remitting multiple sclerosis (RRMS) and are between the ages of 18-65, you may want to join this study evaluating a new investigational drug that may help you reduce you relapses. Participation is voluntary. Qualified volunteers will receive study-related medical evaluations and study drug at no cost. Compensation for time and reasonable reimbursement for travel related expenses are available.

 

For more information, contact:

Michelle Rainka, Pharm.D.” 716-250-2038

Amanda Jamison: 716-819-4117

 

 

          PreferMS

Are you currently being treated for a relapsing remitting form of multiple sclerosis? If so,  you could be eligible to participate in a voluntary research study being conducted to evaluate different medications that treat relapsing remitting forms of multiple sclerosis.

 

To qualify for this study, you must:

·         Be between the ages of 18 and 65,

·         Have been diagnosed with a relapsing remitting form of MS

·         Are naïve to treatment; or have 5 years or less of total lifetime exposure to one class of Disease Modifying Therapy

 

Qualified participants will receive study-related exams and study medication at no cost.

 

For more information, contact:

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

Or visit www.rrmsresearchstudy.com

 

 

HEADACHE/MIGRAINE RESEARCH

Childhood and Adolescent Migraine Prevention Study (CHAMP STUDY)

This is a Double-Blind, Placebo-Controlled  research study to test two medicines for migraine prevention in children and teens. We want to see if amitriptyline and/or topiramate are better than placebo in reducing headache frequency. Children and teens who have migraine headaches and are 8-17 years of age may be eligible to participate in this study. Families will be paid for costs (such as travel,parking,and meals) associated with participation in this research study .

 

-ElectroCore - CH-US-01: Cluster Headache Device Trial

An FDA approved research study for a nonpharmaceutical, non-invasive investigational vagus nerve stimulation treatment for cluster headache. 
Qualified Participants will be:
Men and Women between the ages of 18-75
Have a diagnosis of episodic or chronic cluster headaches
Must be in a current cluster that is expected to last at least 4 weeks


-QuestCore - Acthar Study

A Randomized, Open-Label, Parallel Two-Arm Study Evaluating the Efficacy of H.P. Acthar Injection Gel in the treatment of Adults with Intractable Chronic Migraine.
Qualified Participants will be:
Men and Women between the ages of 18-60
Has a history of chronic migraine
Patients who have failed multiple treatments including botox

 

-Allergan - Botox - (Pediatric Study)

To evaluate the efficacy and safety of a single treatment cycle with 2 dosages of intra-muscular injected botox compared to placebo in adolescents with chronic migraine.Male or Female 12-18 years of age
Medical history of chronic migraine for at least 6 months prior to screening
Subject must be able to follow study instructions, as well as complete required visits and a daily headache diary.


-Allergan - Botox - (Adult Study)

This is a multicenter, randomized, double-blind, placebo controlled, parallel-group study
The purpose of this study is to investigate the burden of chronic migraine and patient treatment benefit for products developed to treat chronic migraine.
Men and Women between the ages of 18-65
Medical history of chronic migraine for at least 6 months prior to screening

 

TREXIMET Aura Clinical Trial

Sponsored by Laszlo L. Mechtler, M.D.

A parallel two arm, double blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.

Qualified participants will be:

  • 18 to 50 years of age, inclusive
  • Carry a diagnosis of 1-2 migraine with aura per month for at least three months before study inclusion
  • Have an onset of a visual aura that occurs 15-30 minutes before a migraine headache
  • Able to understand and complete a migraine diary
  • In generally good health as confirmed by medical and medication history
  • Female subjects must be either a) postmenopausal for one year, b) surgically sterile, c)on acceptable birth control for at least 1 month prior to screening and throughout the study, or d) practicing abstinence and agree to continue same throughout study.

FOR MORE INFORMATION CONTACT:
Olga I. Ananina, Clinical Research Coordinator: 716-558-5670

 

BRAIN TUMOR/ONCOLOGY RESEARCH

Celldex Therapeutics, Inc. - CDX110-04: Glioblastoma Vaccine Trial

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The "ACT IV" Study)

Inclusion Criteria:

  • Men and women who are 18 years of age or older
  • Histologically confirmed, newly diagnosed, de novo glioblastoma, including the following recognized variants of glioblastoma: small cell glioblastoma, giant cell glioblastoma, gliosarcoma and glioblastoma with oligodendroglial component (central pathologic review will be performed and histologic confirmation will be required prior to study entry)
  • Attempted surgical resection followed by conventional chemoradiation
  • Tumor tissue specimens from surgical resection must be available for central pathology review
  • No evidence of progressive disease from the post-operative period to the post-chemoradiation period, based on changes in the neurologic exam, steroid use, or evident radiographic progression
  • Personally signed and dated informed consent document indication that the patient has been informed of and agreed with all pertinent aspects of the study
  • Willing to accept randomization

FOR MORE INFORMATION CONTACT:
Olga I. Ananina, Clinical Research Coordinator: 716-558-5670